eupalinolide-a and Liver-Neoplasms

eupalinolide-a has been researched along with Liver-Neoplasms* in 2 studies

Other Studies

2 other study(ies) available for eupalinolide-a and Liver-Neoplasms

ArticleYear
Eupalinolide B inhibits hepatic carcinoma by inducing ferroptosis and ROS-ER-JNK pathway.
    Acta biochimica et biophysica Sinica, 2022, Jul-25, Volume: 54, Issue:7

    Primary hepatic carcinoma is a common malignant tumor. The classic molecular targeted drug sorafenib is costly and is only effective for some patients. Therefore, it is of great clinical significance to search for new molecular targeted drugs. Eupalinolide B (EB) from

    Topics: Carcinoma, Hepatocellular; Ferroptosis; Humans; Lactones; Liver Neoplasms; MAP Kinase Signaling System; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Sorafenib

2022
Eupalinolide A induces autophagy via the ROS/ERK signaling pathway in hepatocellular carcinoma cells
    International journal of oncology, 2022, Volume: 61, Issue:5

    Hepatocellular carcinoma is the most common primary malignancy of the liver. The current systemic drugs used to treat hepatocellular carcinoma result in low overall survival time. It has therefore been suggested that new small‑molecule drugs should be developed for treating hepatocellular carcinoma.

    Topics: Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Lactones; Liver Neoplasms; Reactive Oxygen Species; Sesquiterpenes, Germacrane; Signal Transduction

2022